Accustem Sciences Inc.
Accustem Sciences Inc.
Your view on ACUT
Overview
What the company does, where it operates, and who runs it.
About Accustem Sciences Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Wendy E. Blosser
- Headquarters
- 5 Penn Plaza, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Wendy E. Blosser
- Headquarters
- 5 Penn Plaza, New York City, NY, US
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Accustem Sciences Inc., and the rating behind it. ACUT last traded at $0.44; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Accustem Sciences Inc.. Starting points for Accustem Sciences Inc.: EPS -$0.11, beta 2.38 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Accustem Sciences Inc.. Accustem Sciences Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Accustem Sciences Inc.. Trailing twelve-month EPS for Accustem Sciences Inc. stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Accustem Sciences Inc.. Accustem Sciences Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Accustem Sciences Inc. valued side by side against its closest peers. Accustem Sciences Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Accustem Sciences Inc., and how their positions are changing. At a $7.1M market value, institutional positions materially move Accustem Sciences Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Accustem Sciences Inc. executives and directors. Shares of Accustem Sciences Inc. have traded between $0.24 and $2.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Accustem Sciences Inc.. Accustem Sciences Inc. is a $7.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Accustem Sciences Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Accustem Sciences Inc.. Coverage tracks Accustem Sciences Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.